Results 51 to 60 of about 7,553 (206)

Bruton Tyrosine Kinase Inhibitors

The Cancer Journal, 2019
Abstract Bruton tyrosine kinase (BTK) is a nonreceptor tyrosine kinase that plays a central role in the signal transduction of the B-cell antigen receptor and other cell surface receptors, both in normal and malignant B lymphocytes. B-cell antigen receptor signaling is activated in secondary lymphatic organs and drives the proliferation of ...
openaire   +3 more sources

Mutations of Bruton's tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia [PDF]

, 2010
Mutations in Bruton's tyrosine kinase (BTK) gene are responsible for X-linked agammaglobulinemia (XLA), which is characterized by recurrent bacterial infections, profound hypogammaglobulinemia, and decreased numbers of mature B cells in peripheral blood.
OLIVEIRA JÚNIOR, E.B., RAMALHO, V.D., ROXO JÚNIOR, P., TANI, S.M., VILELA, M.M.S.   +4 more
core   +2 more sources

The Different Faces of Chronic Lymphocytic Leukemia -Two Clinical Cases [PDF]

Journal of Biomedical & Clinical Research, 2020
Chronic lymphocytic leukemia is one of the most common types of leukemia affecting adults over 65 years of age [1]. The disease is a part of the so-called indolent lymphomas and has a variable clinical course, defined by many factors.
Vanya Popova, Kalina Ignatova, Dobromir Nguen, Pencho Tonchev, Doroteya Todorieva, Lachezar Bogdanov   +5 more
doaj   +3 more sources

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. [PDF]

, 2017
Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-κB. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown.
Brennan, Cameron W., Campos, Carl, Clark, Owen, Codega, Paolo, DeAngelis, Lisa M., Dogan, Ahmet, Gavrilovic, Igor T., Glass, Jon, Graeber, Thomas G., Grommes, Christian, Gutin, Philip H., Hamlin, Paul, Hatzoglou, Vaios, Hsieh, Wan-Ying, Huse, Jason T., Kaley, Thomas J., Lallana, Enrico C., Mellinghoff, Ingo K., Moskowitz, Craig H., Nichol, Donna, Nolan, Craig P., Noy, Ariela, Omuro, Antonio, Palaskas, Nicolaos, Palomba, M. Lia, Panageas, Katherine S., Pastore, Alessandro, Peak, Scott, Pentsova, Elena, Reiner, Anne S., Rohle, Dan, Rosenblum, Marc, Sauter, Craig S., Schartz, Derrek, Schultz, Nikolaus, Tabar, Viviane S., Tang, Sarah S., Thomas, Alissa A., Tsyvkin, Elina, Viale, Agnes, Wolfe, Julia, Won, Minhee   +41 more
core   +2 more sources

Targeting Spleen Tyrosine Kinase-Bruton’s Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis [PDF]

BioMed Research International, 2014
The importance of B-cell activation and immune complex-mediated Fc-receptor activation in the pathogenesis of immunologically mediated glomerulonephritis has long been recognized. The two nonreceptor tyrosine kinases, spleen tyrosine kinase (Syk) and Bruton’s tyrosine kinase (Btk), are primarily expressed by hematopoietic cells, and participate in B ...
Jin-Shuen Chen, Li-Chien Chang, Shyh-Jer Huang, Chao-Wen Cheng   +3 more
openaire   +2 more sources

Ibrutinib inhibits platelet integrin αIIbβ3 outside-in signaling and thrombus stability but not adhesion to collagen [PDF]

, 2015
OBJECTIVE: Ibrutinib is an irreversible Bruton tyrosine kinase inhibitor approved for treatment of Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, and mantle cell lymphoma that increases the risk of bleeding among patients. Platelets from
Alexander P. Bye, Alexander R. Stainer, Amanda J. Unsworth, Jonathan M. Gibbins, Michael J. Fry, Oda A, Sakthivel Vaiyapuri   +6 more
core   +1 more source

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia

Respiratory Medicine Case Reports, 2017
We report a case of invasive pulmonary aspergillosis in a patient taking ibrutinib, a Bruton's tyrosine kinase inhibitor used to treat refractory chronic lymphocytic leukemia.
Benjamin Arthurs, MD, Kathy Wunderle, MD, Maylee Hsu, MD, Suil Kim, MD, PhD   +3 more
doaj   +1 more source

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib [PDF]

, 2016
Activating mutations in MYD88 are present in approximately 95% of patients with Waldenstrom Macroglobulinemia (WM), as well as other B-cell malignancies including ABC DLBCL. In WM, mutated MYD88 triggers activation of BTK. Ibrutinib, a pleiotropic kinase
Advani, Bohers, Cao, Cao, Cheng, Chng, Christopher J. Patterson, Evans, Farré, Gay, Guang Yang, Gutiérrez, Hallek, Hanke, Hong, Honigberg, Janz, Jennifer R. Brown, Jiaji G. Chen, Jie Chen, Jorge J. Castillo, Jourdan, Juilland, Lam, Leleu, Li Tan, Lian Xu, Messeguer, Musumeci, Nathanael Gray, Ngo, Nicholas Tsakmaklis, O’Boyle, Patricelli, Pecquet, Pene-Dumitrescu, Philip Cohen, Poh, Sahota, Saito, Sanner, Sara J. Buhrlage, Schaeffer, Shuai Liu, Steven P. Treon, Suh, Taguchi, Treon, Treon, Treon, Trott, Varettoni, Wei Zhang, Wilson, Woyach, Xia Liu, Xiaofeng Zhang, Xu, Yang, Yang, Zachary R. Hunter   +60 more
core   +2 more sources

A novel Bruton's tyrosine kinase inhibitor JDB175 shows potent efficacy to suppress central nervous system lymphoma

MedComm, 2023
Patients with central nervous system (CNS) lymphoma face limited treatment options and poor treatment outcomes, emphasizing the urgent need for effective therapeutic strategies.
Yong Xia, Xue Li, Ning Jiang, Xiawei Wei
doaj   +1 more source

Prolonged and tunable residence time using reversible covalent kinase inhibitors. [PDF]

, 2015
Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.
Angelina Bisconte, Dane E. Karr, Danny Tam, David Finkle, David G. Loughhead, David M. Goldstein, Erik Verner, J. Hill, J. Michael Bradshaw, Jack Taunton, Jens Oliver Funk, Jesse M. Mcfarl, Jin Shu, Ken A. Brameld, Mary E, Philip A. Nunn, Principia Biopharma, Sergei Romanov, Timothy D. Owens, Tony Ton, Vaishali Patel, Vernon T. Phan, Ville O. Paavilainen, Xiaoyan Li   +23 more
core